Silicon Investor (SI) -- The First Internet Community

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Biotech / Medical : InterMune (nasdaq)ITMN -- Ignore unavailable to you. Want to Upgrade?

To: IRWIN JAMES FRANKEL who wrote (336)	11/5/2002 8:45:43 AM
From: quidditch	Read Replies (1) \| Respond to of 508

Thanks, IJ, What is the date of the CHEST meeting, at which further analysis of the recently completed P3 study (as well as additional weeks of actimmune vs. placebo on an unblinded basis) may be discussed? Is this Philadelphia? Thanks, quid PS Can always tell an early AM ITMN release will be under your moniker. By the way, what is a "prospective" randomized PIV clinical trial?

To: IRWIN JAMES FRANKEL who wrote (336)	11/5/2002 9:06:55 AM
From: IRWIN JAMES FRANKEL	Respond to of 508

The PIV Infergen data appears to be as good or better in producing SVR than Peg-Rebetron. I say "appears" because I do not know the composition of the PIV by genotype. But if there is any substantial genotype 1 group (which should be the case and is supported by some language in the PR) in the study then Infergen is the better drug even when compared to the peyglated versions. That is better than I could have hoped. ij Comparative data: janis7hepc.com See sections Summary of FDA Peg-Intron Hearing and Ribavirin (RBV) Weight Based Dosing

To: IRWIN JAMES FRANKEL who wrote (336)	11/5/2002 9:22:26 AM
From: quidditch	Read Replies (1) \| Respond to of 508

<Dr. Sjogren and colleagues reported that all patients in the study received the same dose of ribavirin. However, a retrospective analysis demonstrated those patients who received the appropriate dose of ribavirin based on their weight (i.e., greater than 10.6 mg/kg per day) achieved a higher sustained viral response rate in both treatment arms: 75% SVR for the Infergen/ribavirin treated patients and an SVR rate of 52% for the Rebetron arm of the study.> On the surface, this would appear to suggest that the apparent advantage of Infergen as vs. Rebetron is enhanced when ribavirin dosage is modulated by weight of the patients.